News Update

UIDAI's AI-Powered Aadhaar Face Authentication sees over 130.5 Crore transactionsGST - Via automated email and SMS on registered mobile number, SCNs were sent for all periods - Only for 2019-20, petitioner states that he did not receive copy and which is not possible to accept - Nonetheless, petitioner permitted to file appeal: HCMinister urges CBI to establish State-of-the-Art Cyber Forensic LabsGST - Respondent department has failed to assign any valid reason justifying the action of cancellation of registration and that too with retrospective effect: HCMHI log sales of more than one million of EVs in FY 2024-25Cus - Classification of product is a recurring and a legal issue - Court deems it appropriate to remand the matter to CESTAT, for a fresh adjudication on the classification issue itself: HCFM launches 'NITI NCAER States Economic Forum' PortalCus - T-3 IGI - Gold bangles weighing 50 grams seized - Since one year period has elapsed, no SCN can be issued - Detention impermissible: HCGST and the tipping pointCus - Old iPhones seized - Whether SCN was delivered to petitioner within prescribed period is a question of fact - Reply to be filed and provisional release may be sought: HCGovt amends quality control order for vinyl acetate monomerCX - Co-noticees cannot be held liable once the main noticees have resolved the matter under SVLDRS, as no further liability exists for them: CESTATGovt notifies 7.1% interest rate for Special Deposit Scheme for non-govt Provident FundsCus - The right to a fair hearing is fundamental and must be upheld even if procedural lapses occur on the part of appellant or department: CESTATGovt makes Aadhaar mandatory for receiving MSME benefitsST - Extended limitation - Department can request further documents or conduct an inquiry if duty escapes assessment; audit process should not be used as basis to assume suppression of facts: CESTATGovt revises procurement guidelines to give preference to domestically-manufactured iron and steelST - Department cannot invoke extended limitation on charges of evasion of tax, where it is aware of assessee's activities during relevant period: CESTATIndia delivers 625 MT of relief materials to quake-devastated MyanmarST - Allegations of suppression of facts with intent to evade payment of tax, do not hold where based on open-source documents & where issue involves interpretation of law: CESTATWorld waits with baited breath for Trump’s reciprocal tariff todayI-T - If AO had issued notice u/s 148A(b) which is much earlier to time-limit stipulated, i.e. within three years, then same can't be challenged on ground of limitation period: HCBatman, Val Kilmer, breathes last at 65India’s defence exports peaked to Rs 24K Crore in last fiscal: RMI-T- Re-assessment invalid where reasons therefor did not clearly identify any material facts that were not disclosed during original assessment: HCTrump freezes federal grants to Princeton Univ
 
G20 Health Meet: India favours global collaboration network on R&D

By TIOL News Service

NEW DELHI, JUNE 07, 2023: "IT is through initiatives like the Global R&D Network that we can collectively build a future where no one is left behind, and access to life-saving medical countermeasures becomes a universal reality". This was stated by S Aparna, Secretary, Dept. of Pharmaceuticals while delivering the closing remarks at the concluding session of the 3rd G20 Health Working Group Meeting, here yesterday. She was joined by Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH and Dr Rajiv Bahl, Secretary, Dept of Health Research and DG, ICMR.

Addressing the session, S Aparna expressed her appreciation towards all the delegates from G20 member states, invited countries, and International Organizations for contributing their valuable insights on the establishment of a global R&D network within the Global Medical Countermeasures Platform to support Pandemic Preparedness and Response. She stated that "the discussions have helped to define the pathway for collaborative partnerships and provided us with a framework to envision the global R&D network."

Underscoring the impact of the COVID-19 pandemic on the healthcare systems around the world, the Union Pharma Secretary said that "the time is now to build collaboration among nations, institutions, and stakeholders through a global R&D network that fosters innovation and accelerates research. This would be a necessary element to build the requisite agility and bench strength on a global scale to predict, prepare for and respond to future health emergencies in a robust, equitable and timely manner".

She emphasized on "the power of collective action and partnerships in expediting research and development, as a necessary precursor to equitable distribution, and access to life-saving medical countermeasures against epidemic and endemic diseases". "The timely deployment of appropriate countermeasures in an emergency, also relies to a large extent, on those having been developed and tested by continuous interaction with a variety of stakeholders in different locations and socio-economic situations during peace time", she further stated.

Noting that deliberations over the course of the last three days have delved into the fundamental principles and components required to establish a thriving network that enhances capabilities for early stage and preparatory research, and ensures universal access to effective and affordable medical countermeasures, she stated that "key aspects such as leveraging the respective strengths of partners, structured knowledge sharing, prioritization, resource allocation, capacity building, and effective technology transfer have been identified as essential pillars of a well-functioning global R&D network."

On the structure of such a mechanism, S Aparna stated that "a Network of Networks which encouraging regional and local cooperation as well as greater alignment of existing partnerships and principles such as those found in World Health Organization (WHO) Blueprint for epidemics and the 100 days Mission would be an efficient and effective path towards Impact driven Collaboration" "That such a collaboration on R&D should factor in a globally accessible database covering priority pathogens, ongoing research on vaccines, therapeutics and diagnostics (VTDs), and development of disease agnostic technologies would help to address challenges such as the asymmetry of information, the lack of availability of critical materials, low attention to certain products needed by small patient populations as well as the inequitable access to potential solutions that currently obtains across geographies and communities", she stated.

 


POST YOUR COMMENTS